This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vuist, W. M. J. Articles by Melief, C. J. M. Search for Related Content PubMed PubMed Citation Articles by Vuist, W. M. J. Articles by Melief, C. J. M.

Two Distinct Mechanisms of Antitumor Activity Mediated by the Combination of Interleukin 2 and Monoclonal Antibodies

Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Previously we described a human B-lymphoma xenotransplantation model in which the immunotherapeutic activity of monoclonal antibodies (mAbs), directed against human B-cell antigens, can be studied. An anti-CD19 mAb of IgG2a subclass was therapeutically active by itself in this model, and its efficacy was increased by simultaneous administration of recombinant interleukin 2 (rIL-2). Immunotherapy with IgG1 or IgG2b isotype variants of an anti-CD19 mAb was ineffective if given alone. We now show that the combination of these ineffective isotype variants with rIL-2 results in significant antitumor effects, although IgG2a anti-CD19 mAb in combination with rIL-2 was therapeutically more active.

In vitro studies of the effector mechanisms possibly involved in these treatment modalities indicate that the antitumor activity of IgG1 or IgG2b anti-CD19 mAbs in combination with rIL-2 may be mediated by rIL-2-induced antibody-dependent cellular cytotoxic activity of lymphocytes. The antitumor effect of IgG2a anti-CD19 mAb in combination with rIL-2 may be mediated not only by rIL-2-induced antibody-dependent cellular cytotoxic activity of lymphocytes but also by IgG2a-restricted antitumor activity of monocytes/macrophages. These results may explain the greater in vivo efficacy of treatment with rIL-2 and IgG2a subclass mAb versus treatment with rIL-2 and IgG1 or IgG2b subclass mAbs.

¹ Supported by Grant NKI-84-14 from the Koningin Wilhelmina Fonds (The Netherlands Cancer Foundation).

² To whom requests for reprints should be addressed.

Received 3/28/90. Accepted 6/14/90.

This article has been cited by other articles:

				N. Yazawa, Y. Hamaguchi, J. C. Poe, and T. F. Tedder Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease PNAS, October 18, 2005; 102(42): 15178 - 15183. [Abstract] [Full Text] [PDF]